ISPAN Perfluoropropane C3F8 Gas
Airgas Therapeutics, LLC · Decision date Apr 30, 2026
What did the FDA decide?
FDA records P900066/S017 as a supplement to PMA P900066, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 30, 2026.
FDA approval order statement
Approval to institute Agilent 8890 gas chromatograph and Metrohm 930 ion chromatograph as redundant instruments for the final product release testing.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Apr 30, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P900066/S017
- Regulatory pathway
- PMA supplement
- Applicant
- Airgas Therapeutics, LLC
- Product code
- LPO
- Decision code
- OK30
- Decision date
- Apr 30, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Gases used within eye to place pressure on detached retina.
- Applicant
- Airgas Therapeutics, LLC
- Product code
- LPO
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P900066/S017 received
Application receipt date recorded by FDA.
P900066/S017 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P900066. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
Other records with product code LPO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | Sep 30, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | May 28, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | May 28, 2026 | FDA | |
| Alcon Research, LLC | PMA supplement | Feb 17, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Airgas Therapeutics, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6141 Easton Rd., Plumsteadville, PA, 18949
Sources and methodology
- Original FDA record: P900066/S017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



